GlaxoSmithKline: Sleep Initiation and Maintenance Disorders trials
The registry lists 13 Sleep Initiation and Maintenance Disorders studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 1 have results posted.
Phase 1 5Phase 2 7Phase 3 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.CompletedNCT00699608Phase 3Results posted
- Vestipitant 28-day Tolerance StudyCompletedNCT00992160Phase 2
- A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary InsomniaCompletedNCT00650871Phase 2
- A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary InsomniaCompletedNCT00606697Phase 2
- A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female PopulationWithdrawnNCT00534872Phase 1
- Radiolabel Study In Healthy Volunteers For Insomnia-Targeting DrugCompletedNCT00520663Phase 1
- 15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.CompletedNCT00495729Phase 1
- Bioequivalence and Food Effect Study in Healthy VolunteersCompletedNCT00495274Phase 1
- Disturbed Sleep Model Study.CompletedNCT00440323Phase 1
- To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary InsomniaCompletedNCT00426816Phase 2
- Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary InsomniaCompletedNCT00354809Phase 2
- Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary InsomniaCompletedNCT00280436Phase 2
- Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary InsomniaCompletedNCT00280423Phase 2